New horizons in adjuvants for vaccine development

Trends in Immunology

Volumn 30, Issue 1, 2009, Pages 23-32

  Reed, Steven G ^a   Bertholet, Sylvie ^a   Coler, Rhea N ^a   Friede, Martin ^b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL TOXIN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; ESCHERICHIA COLI EXOTOXIN; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; ISCOM; ISCOMATRIX; MIDGE; MONTANIDE ISA 51; MPL; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; PREPANDRIX; QS 21; QUIL A; RESIQUIMOD; UNCLASSIFIED DRUG; VACCINE;

BASAL CELL CARCINOMA; CHOLERA; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GRANULOMA; HEPATITIS A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEISHMANIASIS; MALARIA; NEOPLASM; NONHUMAN; REVIEW; TUBERCULOSIS; VERRUCA VULGARIS; VESICULAR STOMATITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; HUMANS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VACCINES;

EID: 58149216348     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.09.006     Document Type: Review

References (100)

1. Wack A., and Rappuoli R. Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 17 (2005) 411-418
2. Kenney R.T., and Edelman R. Survey of human-use adjuvants. Expert Rev. Vaccines 2 (2003) 167-188
3. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
4. Kawai T., and Akira S. TLR signaling. Semin. Immunol. 19 (2007) 24-32
5. McGreal E.P., et al. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol. 17 (2005) 18-24
6. Carneiro L.A., et al. Nod-like receptors in innate immunity and inflammatory diseases. Ann. Med. 39 (2007) 581-593
7. Onomoto K., et al. Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr. Top. Microbiol. Immunol. 316 (2007) 193-205
8. Takeuchi O., and Akira S. Recognition of viruses by innate immunity. Immunol. Rev. 220 (2007) 214-224
9. Palsson-McDermott E.M., and O'Neill L.A. Building an immune system from nine domains. Biochem. Soc. Trans. 35 (2007) 1437-1444
10. Pashine A., et al. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11 4, Suppl (2005) S63-S68
11. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27 (2007) 363-371
12. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12 (2000) 456-463
13. Kono H., and Rock K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8 (2008) 279-289
14. Allison A.C., and Byars N.E. Adjuvant formulations and their mode of action. Semin. Immunol. 2 (1990) 369-374
15. Bojang K.A., et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23 (2005) 4148-4157
16. Pichyangkul S., et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22 (2004) 3831-3840
17. Chwalek M., et al. Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. Biochim. Biophys. Acta 1760 (2006) 1418-1427
18. Scheerlinck J.P., and Greenwood D.L. Virus-sized vaccine delivery systems. Drug Discov. Today 13 (2008) 882-887
19. Villa L.L., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
20. Peek L.J., et al. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 (2008) 915-928
21. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336 (1997) 86-91
22. Clements C.J., and Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20 (2002) S24-S33
23. Ulanova M., et al. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69 (2001) 1151-1159
24. Seubert A., et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180 (2008) 5402-5412
25. Kool M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 (2008) 869-882
26. Brewer J.M., et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163 (1999) 6448-6454
27. Eisenbarth S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
28. Edelman R. The development and use of vaccine adjuvants. Mol. Biotechnol. 21 (2002) 129-148
29. Burgess M.A., and McIntyre P.B. Vaccines and the cold chain: is it too hot... or too cold?. Med. J. Aust. 171 (1999) 82
30. Ott G., et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13 (1995) 1557-1562
31. Wadman M. Race is on for flu vaccine. Nature 438 (2005) 23
32. Straus S.E., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176 (1997) 1129-1134
33. Heineman T.C., et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17 (1999) 2769-2778
34. McFarland E.J., et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184 (2001) 1331-1335
35. Ott G., et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol 6 (1995) 277-296
36. Podda A., and Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2 (2003) 197-203
37. Radosevic K., et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 26 (2008) 3640-3646
38. Baldridge J.R., and Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19 (1999) 103-107
39. Brandenburg K., and Wiese A. Endotoxins: relationships between structure, function, and activity. Curr. Top. Med. Chem. 4 (2004) 1127-1146
40. Johnson D.A. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr. Top. Med. Chem. 8 (2008) 64-79
41. Mueller M., et al. Aggregates are the biologically active units of endotoxin. J. Biol. Chem. 279 (2004) 26307-26313
42. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
43. Reed S., and Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect. 7 (2005) 922-931
44. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21 (2005) 244-249
45. Reed S.G., et al. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev. Vaccines 2 (2003) 239-252
46. Marchand M., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39 (2003) 70-77
47. Wheeler A.W., and Woroniecki S.R. Allergy vaccines-new approaches to an old concept. Expert Opin. Biol. Ther. 4 (2004) 1473-1481
48. Alderson M.R., et al. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12 (2006) 313-319
49. Gluck R., et al. Adjuvant and antigen delivery properties of virosomes. Curr. Drug Deliv. 2 (2005) 395-400
50. Holzer B.R., et al. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14 (1996) 982-986
51. Gluck R., et al. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. 4 (2004) 1139-1145
52. Wu H.Y., and Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16 (1998) 286-292
53. Ryan E.T., and Calderwood S.B. Cholera vaccines. Clin. Infect. Dis. 31 (2000) 561-565
54. Hill D.R., et al. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 6 (2006) 361-373
55. Aucouturier J., et al. The use of oil adjuvants in therapeutic vaccines. Vaccine 24 (2006) 44-45
56. Scalzo A.A., et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69 (1995) 1306-1309
57. Wu Y., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3 (2008) e2636
58. Kensil C.R., et al. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 6 (1995) 525-541
59. Pearse M.J., and Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 57 (2005) 465-474
60. Jiang W., et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375 (1995) 151-155
61. Mahnke K., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151 (2000) 673-684
62. Harding C.V., et al. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 147 (1991) 2860-2863
63. van Binnendijk R.S., et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176 (1992) 119-128
64. Ackerman A.L., et al. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12889-12894
65. Houde M., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 425 (2003) 402-406
66. Guermonprez P., et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425 (2003) 397-402
67. Desombere I., et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 20 (2002) 2597-2602
68. Sambhara S., et al. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Cell. Immunol. 210 (2001) 1-4
69. Rimmelzwaan G.F., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19 (2000) 1180-1187
70. Ennis F.A., et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 (1999) 256-261
71. Allison A.C., and Byars N.E. Syntex adjuvant formulation. Res. Immunol. 143 (1992) 519-525
72. Byars N.E., et al. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine 9 (1991) 309-318
73. Byars N.E., et al. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 8 (1990) 49-56
74. White A.C., et al. A purified saponin acts as an adjuvant for a T-independent antigen. Adv. Exp. Med. Biol. 303 (1991) 207-210
75. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17 (1999) 1075-1081
76. Bovier P.A., et al. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J. Travel Med. 6 (1999) 228-233
77. Jacques P., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 (2002) 3644-3649
78. Bienzle U., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38 (2003) 811-819
79. McCormack S., et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18 (2000) 1166-1177
80. Keam S.J., and Harper D.M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed). Drugs 68 (2008) 359-372
81. Audibert F., et al. Dissociation of immunostimulant activities of muramyl dipeptide (MDP) by linking amino-acids or peptides to the glutaminyl residue. Biochem. Biophys. Res. Commun. 96 (1980) 915-923
82. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4 (2004) 595-602
83. Harandi A.M., and Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr. Opin. Investig. Drugs 5 (2004) 141-145
84. Higgins D., et al. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines 6 (2007) 747-759
85. Akira S. TLR signaling. Curr. Top. Microbiol. Immunol. 311 (2006) 1-16
86. Gorden K.B., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174 (2005) 1259-1268
87. Miranda-Verastegui C., et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 40 (2005) 1395-1403
88. Stockfleth E., et al. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. 149 Suppl 66 (2003) 53-56
89. Slade H.B., et al. Imiquimod 5% cream (Aldara). Expert Opin. Investig. Drugs 7 (1998) 437-449
90. Zurbriggen R., et al. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines 2 (2003) 295-304
91. Salmond R.J., et al. Immune modulation by the cholera-like enterotoxins. Expert Rev. Mol. Med. 4 (2002) 1-16
92. Barackman J.D., et al. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 8 (2001) 652-657
93. Ryan E.J., et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67 (1999) 6270-6280
94. Lee H.H., et al. Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J. Exp. Med. 205 (2008) 2269-2280
95. Kumar R., and Burns E.A. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev. Vaccines 7 (2008) 467-479
96. De Donato S., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 (1999) 3094-3101
97. Borkowsky W., et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J. Infect. Dis. 181 (2000) 890-896
98. Mitchell D.K., et al. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr. Infect. Dis. J. 24 (2005) 925-927
99. Conroy H., et al. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27 (2008) 168-180
100. Bayry J., et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10221-10226